Estimates of costs for modelling return on investment from smoking cessation interventions

Abstract

© 2018 The Authors. Background and aims: Modelling return on investment (ROI) from smoking cessation interventions requires estimates of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco smoking and costs of implementing cessation interventions for a Europe-wide ROI model (EQUIPTMOD).

Design: Focused search of administrative and published data. A standardized checklist was developed in order to ensure consistency in methods of data collection. .

Setting and participants: Adult population (15+ years) in Hungary, Netherlands, Germany, Spain and England. For passive smoking related costs, child population (0-15 years) was also included.

Measurements: Costs of treating smoking attributable diseases; productivity losses due to smoking attributable absenteeism; and costs of implementing smoking cessation interventions. .

Findings: Annual costs (per case) of treating smoking attributable lung cancer were between €5,074 (Hungary) and €52,106 (Germany); coronary heart disease between €1,521 (Spain) and €3,955 (Netherlands); chronic obstructive pulmonary disease between €1,280 (England) and €4,199 (Spain); stroke between €1,829 (Hungary) and €14,880 (Netherlands). Costs (per recipient) of smoking cessation medications were estimated to be: for standard duration of varenicline between €225 (England) and €465 (Hungary); for bupropion between €25 (Hungary) and €220 (Germany). Costs (per recipient) of providing behavioral support were also wide-ranging: one-to-one behavioural support between €34 (Hungary) and €474 (Netherlands); and group-based behavioural support between €12 (Hungary) and €257 (Germany). The costs (per recipient) of delivering brief physician advice were: €24 (England); €9 (Germany); €4 (Hungary); €33 (Netherlands); and €27 (Spain).

Conclusions: Costs of treating smoking-attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions.